BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report sent to investors on Friday. The firm issued a sell rating on the medical technology company’s stock.

Other equities research analysts also recently issued reports about the stock. Maxim Group downgraded shares of BIOLASE from a strong-buy rating to a hold rating in a research report on Friday, May 24th. Benchmark reaffirmed a speculative buy rating and set a $0.40 price objective on shares of BIOLASE in a report on Monday, August 12th.

BIOLASE Price Performance

BIOLASE stock opened at $0.06 on Friday. The stock’s 50 day moving average price is $0.08 and its 200 day moving average price is $0.15. The company has a market cap of $1.87 million, a PE ratio of 0.00 and a beta of 0.71. BIOLASE has a 1-year low of $0.04 and a 1-year high of $5.95.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. The company had revenue of $11.56 million for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its stake in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.79% of the company’s stock.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.